This is an appeal from a decree dismissing plaintiff’s complaint for an injunction against violations of § 301(a), (b), and (k) for the shipment of misbranded articles of drug and § 502 of the Federal Food, Drug, and Cosmetic Act of 1938, c. 675, 52 Stat. 1040, 21 U.S.C.A. § 331(a), (b), and (k) and § 352(a).
The complaint charged that defendant had caused to be printed circulars making therapeutic claims for the products which he manufactures, falsely claiming that the produсts will cure and constitute adequate treatment for human ailments; that such circulars were sent in interstate commerce to agents аnd distributors of said products, separately from the products to which they relate; and that by virtue of defendant’s power and control over his agents and distributors, he required them to display the separately shipped circulars with defendant’s products.
We must decide whether the act of bringing printed matter containing false and misleading therapeutic claims in the presence of, and in association with, an article after shipment in interstate commerce, results in the article being mis-branded in violation of § 301 (k) of the Act.
The Federal Food, Drug, and Cоsmetic Act, so far as material, provides :
“Sec. 201 [§ 321]. For the purposes of this Act [chapter]—
J¡í J¡í sj< *
“(m) The term ‘labeling’ means all labels and other written, printed, or graphic matter (1) upon any аrticle or any of its containers or wrappers, or (2) accompanying such article.
* Sf« * * * *
“Sec. 301 [§ 331]. The following acts and the causing thеreof are * * * prohibited :
“(a) The introduction or delivery for introduction into interstate commerce of any * * * drUg, * * * that is * * * misbranded.
“(b) The * * * misbranding of аny * * * drug * * * in interstate commerce.
* H* * * sfc *
“(k) The alteration, * * * of * * * any part of the labeling of, or the doing of any other act with respect to, a * * * drug, * * * if such act is done while such article is held for sale after shipment in interstate commerce and results in such article being misbranded.
j|« jf:
“Sec. 502 [§ 352], A drug or device shall be deemed to be misbranded — ■
“(a) If its labeling is false or misleading in any particular.”
In the District Court counsel for plaintiff contended that the phrase “accompanying such article” means that misbranding occurs through any device which causes printed mattеr containing false therapeutic claims to be shipped through interstate commerce, including printed matter shipped sepаrately from the product, and constitutes a violation of § 201 (m) if at the destination it becomes associated with and is used in proximity to the transported product on the shelves and display counters of the defendant’s agents and distributors.
The District Court [
Section 8 of the Food and Drugs Act of 1906 provided that the term “misbrand-ed” should apply to all drugs, or articles of food, the package or label of which bore any statement, design, or device regarding such article, which was false or misleading in any particular, 21 U.S.C.A. § 9. In interpreting this section, it was held that
*466
a circular
enclosed
with an article inside the carton in which it was offered for sale was not within the purview of this section. United Statеs v. American Druggists’ Syndicate, C.C.,
We have not had the benefit of a brief on behalf of the defendant, but in the District Court the defendant сontended that the word “accompany” did not include literature which did not go along with the product — in other words, that the test was not nearness, concurrence of display, or availability for reading. With this contention we cannot agree.
The word “accompany” is not defined in the Act, but we observe that among the meanings attributed to the word are “to go along with,” “to go with or attend as a companion or associate,” and “to occur in association with,” Webster’s New International Dictionary, 2d Ed. There can be no question that amоng the usual characteristics of labeling is that of informing a purchaser of the uses of an article to which the labeling relates, and that the basic character of the Federal Food, Drug, and Cosmetic Act is not directly concerned with the sale of the products thеrein described, or whether the literature is carried away by the purchaser. It was enacted to protect the public health аnd to prevent fraud, and it ought to be given a liberal construction. Consequently, we are impelled to the conclusion that misbranding is cognizable under the Act if it occurs while the articles are being held for sale.
This conclusion is sustained by the legislative history of the Act, from which it aрpears that it was not the purpose of Congress to limit the scope of the phrase “accompanying such articles” to printed matter placed in the carton in which the article is contained. See Senate Report 1944, 73rd Cong., 1st and 2nd Sessions, and Senate Rеport No. 493 of the Committee on Commerce, 73rd Cong., 2nd Sess.
Our conclusion is also sustained by the decision in the case of United States v. Research Laboratories, 9 Cir.,
The decree of the District Court is reversed, and the cause is remanded for further proceedings in conformity with this opinion.
